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A B S T R A C T
In the literature the therapeutic nonequivalence of oxytetracycline hydrochloride (OTCH) capsules and tablets
was attributed to the different aqueous solubility of polymorphs without their comprehensive study. Our aim
was to reveal the effects of polymorphism on equilibrium solubility, dissolution kinetics and the supersaturation
of two OTCH polymorphs (stable Form A and metastable Form B).The equilibrium solubility was measured in
biorelevant pH range 4–7.4 by the standardized saturation shake-flask method. We also studied the solubility in
SGF at pH 1.2 and the effect of the pH change from 1.2 to 5.0 on solubility. The dissolution was studied using
real-time concentration monitoring with an ATR probe attached to a UV spectrophotometer (µDISS Profiler). A
wide spectrum of solid phase analysis methods (SEM, IR, XRPD, Raman) was applied for characterization of
polymorphs and to identify which form is present at the equilibrium solubility. Identical equilibrium solubility
values were obtained at the same pHs in region 4.0–7.4 using the two polymorphs as starting materials. The
XRPD analysis of the isolated solid phases proved that both polymorphic forms were converted to dihydrate
form. In situ monitoring of the dissolution at pH 5.0 showed immediate dissolution, no difference in super-
saturation, and short equilibration time for both forms indicating the immediate conversion. In SGF (pH 1.2)
Form B dissolved better than Form A and showed significantly different dissolution kinetic and stability. A long-
lasting, false chain-citation stating that Form B dissolves 28x better in water than Form A, was cut by the present
study (i) revealing that the cited data was measured in IPA not in water, and (ii) proving that only the intrinsic
solubility of OTC dihydrate can be measured in water due to conversion of polymorphs under the experimental
conditions of solubility measurement. However this conversion is inhibited below pH 1.5, so the differences in
solubility and dissolution kinetic found at pH 1.2 may contribute to the interpretation of the different serum-
levels reported at solid formulations.
API active pharmaceutical ingredient
ATR attenuated total reflection
BR Britton–Robinson buffer







SEM scanning electron microscopy
SGF simulated gastric fluid
SSF saturation shake-flask method
XRPD x-ray powder diffraction
1. Introduction
Polymorphism and the effect of different polymorphic forms of
drugs on PK/PD properties have gained substantial interest in the past
50 years in pharmaceutical sciences and the industry. The theoretical
background and the practical aspects are comprehensively discussed in
books [e.q. Brittain, 1999; Bernstein, 2002; Hilfiker et al., 2006] and
reviews [e.q. Raw et al., 2004; Singhal and Curatolo, 2004; Saifee et al.,
2009; Pangarkar et al., 2013]. In these papers those examples are
https://doi.org/10.1016/j.ejps.2020.105328
Received 29 January 2020; Received in revised form 9 March 2020; Accepted 28 March 2020
⁎ Corresponding author.
E-mail address: novak.krisztina@pharma.semmelweis-univ.hu (K. Takács-Novák).
European Journal of Pharmaceutical Sciences 149 (2020) 105328
Available online 05 April 2020
0928-0987/ © 2020 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license 
(http://creativecommons.org/licenses/BY-NC-ND/4.0/).
T
surveyed in detail where polymorphism of API in formulated and
marketed drugs caused serious safety problems, such as stability issue,
failed dissolution, different plasma levels, and sometimes toxicity.
Among these well-known examples (from chloramphenicol palmitate,
through carbamazepine, enalapril, etc. up to ritonavir) one of the cited
compounds is oxytetracycline.
The story began in the late 60s when Brice and Hammer (1968) first
reported the therapeutic nonequivalence of oxytetracycline hydro-
chloride (OTCH) capsules marketed in the UK. 16 lots of OTCH capsules
from 13 suppliers produced lower antibiotic level in the blood serum
than the originator product (Terramycin, Pfizer). Seven of the lots
produced blood levels below the generally accepted minimum ther-
apeutic level. Similar results were found by Blair et al. (1971) testing 10
OTCH capsules from different manufacturers supplying the US market.
Only 3 were equivalent to the reference product, serum concentrations
of the remaining seven products were significantly lower. Subsequently,
Groves (1973) investigated other orally used solid forms and reported
large differences in the in vitro dissolution performance of OTCH tablets
sourced from different suppliers. Although the existence of various
polymorphic forms of OTCH has been known [Burger et al., 1986],
polymorphism was not mentioned as a possible reason for discrepancies
in dissolution and serum level in the above studies. First
Liebenberg et al. (1999) studied the effect of polymorphism on dis-
solution properties of chemically equivalent OTCH powders. Six OTCH
bulk samples from randomly selected suppliers in South Africa were
characterized by solid phase analysis, and two samples were found as
Form A, and four as Form B. The two polymorphic forms had different
dissolution properties in water and 0.1 M HCl. This difference became
more substantial when the dissolution from tablets prepared with mi-
crocrystalline cellulose in 5:1 (OTCH: Avicel PH 200) ratio was com-
pared. Tablets prepared from Form A dissolved significantly slower in
acidic medium than the others, for example, at 30 min, these tablets
exhibited ~ 55% dissolution, while the Form B containing tablets
achieved ~ 95% dissolution. These important findings - first showing to
the scientific community the possible consequence of polymorphism of
OTCH on bioavailability - however were attributed to the low and
different intrinsic solubility of OTCH polymorphs cited from ref.
[Burger et al., 1986]. The statement in the reference article ‘Form A is
28 times less soluble than Form B’ was however not referring to solubility
measured in water, but in IPA. With this statement, a long-lasting, false
citation chain has been started. Subsequent reviews [e.q. Singhal et al.,
2004; Censi and Di Martino, 2015] mentioned the above aqueous so-
lubility difference as a fact. The characterization of several polymorphs
of OTCH was published [Toro et al., 2007], but the effect of OTCH
polymorphism on solubility/dissolution and its role in therapeutic
nonequivalence has not been revealed. Recently Censi and Di
Martino (2015) have commented on the topic the following way: ‘fur-
ther studies characterizing the physical and chemical properties of
oxytetracycline polymorphs would be useful, as no recent works are
available in the literature’.
In this study, our aims were to analyse the solubility of two poly-
morphic forms of OTCH, namely, Form A and B. We attempted to
measure the equilibrium solubility of the samples in aqueous buffers in
the biorelevant pH range of 4–7.4 by the standardized saturation shake-
flask (SSF) method to reveal the solubility difference between them. We
also studied the solubility in simulated gastric fluid (SGF) at pH 1.2 and
the effect of the pH change from 1.2 to 5.0 on dissolution. Another
purpose of ours was the real-time monitoring of the dissolution profile
using an ATR probe in situ, attached to a UV spectrophotometer (µDISS
Profiler™). A wide spectrum of solid phase analysis methods (SEM, IR,
XRPD, Raman) was applied for characterizing the polymorphs and to
identify which form is present at the solubility equilibrium.
2. Materials and methods
2.1. Materials
OTCH Form A was purchased from Sigma-Aldrich Co. LLC. (St.
Louis, MO, USA) and used without further purification. Form B was
prepared by us from Form A according to the literature method (see
below). Both forms were identified by IR, Raman and XRPD methods.
Both samples were crystalline material, Form A used as was supplied,
Form B after sieving to assure the homogeneity of particle size. Distilled
water of Ph. Eur. grade was used. All other reagents were of analytical
grade.
A Britton–Robinson (BR) buffer stock solution (a mixture of acetic
acid, phosphoric acid, and boric acid, each at 0.04 M) was prepared,
and the required amount of 0.2 M NaOH or 1 M NaOH was added to
reach the pH specified for the solubility experiments.
2.2. Preparation of Form B
Form B was prepared in our laboratory according to Burger et al.,
1986. The recrystallization was made in a reactor with noninvasive
Raman monitoring (Horiba Jobin Yvon, France). Real-time Raman
spectra were fixed in 292–1540 cm−1 spectral range with a 300 mW
laser (785 nm) source and air-cooled CCD detector. 5 g of Form A was
mixed with 20 mL of a solvent mixture consisting of 0.2 M HCl and
MeOH (1:3). The system was heated until getting a clear solution, then
it was cooled using a linear (1 °C/min) rate cooling program. The
temperature was controlled using a Stardom FCN-type PLC manu-
factured by Yokogawa (Japan) and a monofluid thermostat developed
in our Department. A Eurostar power control-visc type stirrer, made by
IKA (Germany), was also controlled by the PLC. The precipitated
crystals were filtered and washed with 2 × 5 mL cold MeOH and dried.
The identification of the polymorphic form was confirmed by IR, XRPD,
and SEM as well.
2.3. Determination of thermodynamic solubility by SSF method
The equilibrium solubility of the samples in pH region 4.0–7.4 was
determined by the standard protocol of SSF method [Baka et al., 2008;
Avdeef et al., 2016]. The sample was added in excess to the aqueous
buffer solutions to produce a suspension. The amount of solid added
was accurately measured: 40–50 mg/5–10 mL. At a controlled tem-
perature of 25.0 ± 0.1 °C the suspension was vigorously stirred for a
period of 6 h, followed by a further 18 h of sedimentation period (stirrer
turned off). For separation of the phases sedimentation was used to
avoid the filtration. Sedimentation has advantages from both theore-
tical and practical point of view, because it does not perturb the dy-
namic equilibrium of solid dissolution/solute precipitation and there is
no adsorption to the filter material what is common upon filtration
[Völgyi et al., 2018]. During the 24 h incubation the sample was pro-
tected from light. At pH 5.0, the solubility measurement was also per-
formed at 37.0 ± 0.1 °C.
The concentration of the saturated solution was measured by UV
spectroscopy using JASCO V 550 UV/vis spectrophotometer. Three
aliquots were carefully withdrawn from the liquid (using a fine glass
pipette), and were diluted with the solvent as necessary. Three replicate
solubility measurements were carried out under each of the tested
conditions. Since OTCH has a pH-dependent UV spectrum, the specific
absorbance (A1%1cm, the absorbance of 1 g/100 mL solution over a 1 cm
optical pathlength at a given wavelength) of OTCH in each BR buffer
used for solubility measurement was determined separately at a se-
lected wavelength using 12 points of two parallel dilution series, from
the linear regression equation (Lambert–Beer law), where the regres-
sion coefficient (r) was higher than 0.9998 in each case. The specific
absorbance data are shown in Table 1.
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2.4. Real-time in situ monitoring of dissolution, supersaturation,
precipitation and equilibration time using ATR UV-probe
The drug solution concentration versus time (0–24 h) profile was
investigated at 25 ± 0.1 °C in BR buffer pH 5.0 with ATR UV-probe
(Hellma Analytics, Germany) attached to the Rainbow Dynamic
Dissolution Monitor of the µDISS Profiler™. Originally the µDISS
Profiler™ instrument (Pion Inc. Billerica MA, US) was designed to
measure real-time concentration with UV fibre optic dip probes inserted
into 8 temperature-controlled 20 mL vessels, stirred with magnetic
stirrer and applying different (2–5–10–20 mm) tips, depending on the
concentration of the solution measured. It is suitable for the analysis of
poorly soluble compounds [Borbás et al., 2018; Takács-Novák et al.,
2019], but cannot be used for OTC due to the high concentration of its
saturated solution even at the pH of the isoelectric point. Therefore, the
ATR UV-probe was immersed into a temperature-controlled 20 mL
vessel, where 50 mg of the samples (Form A or Form B) were added to
10 mL of BR buffer solution pH 5.0 assuring the excess of the solid. The
UV spectra were registered using the following protocol: 1 spectrum/
min for 2 h, 1 spectrum/10 min for 4 h, and 1 spectrum/30 min for
18 h. The stirrer was turned off at 6 h. For the evaluation of the con-
centration, previously determined calibration data and second deriva-
tive spectra were used. Three parallel measurements were performed
with both polymorphs. Light protection was assured.
2.5. Solubility measurement in SGF
Though OTCH dissolves very well at low pH values, the solubility
was investigated in simulated gastric fluid (pH 1.2) as well. 1.0 g
sample (Form A or Form B) was added to 2.0 mL SGF producing a very
turbid, colloidal, foamy, dark brown suspension. After shaking for
20 min, the solubility sample was allowed to stand at a controlled
temperature of 25.0 or 37.0 °C for 1 h. The concentration of the satu-
rated solution was measured after 500x dilution, with a UV fibre optic
dip probe (2 mm tip) coupled with µDISS Profiler™. For evaluation
previously determined calibration data and second derivative spectra
were used.
The real-time monitoring was performed with an ATR-UV probe.
2.5 g of Form A or Form B was added to 3 mL of SGF, and the spectra
were registered using the same protocol as described above. The stirrer
was turned off at 1 h. For the evaluation of the concentration, pre-
viously determined calibration data and second derivative spectra were
used. One measurement was performed with both polymorphs. Light
protection was assured.
2.6. Study of pH-change from 1.2 to 5.0 on solute concentration
A high concentration (20 mg/10 mL) clear solution was prepared
from Form A in SGF. After 20 min, the pH was changed to 5.0 by adding
1.2 mL of concentrated phosphate solution (used for the same purpose
in ref. [Borbás et al., 2018] and called media B), 500 µL of 1 M NaOH,
and 600 µL of 0.2 M NaOH. The opalescence of the solution was visually
assessed, and the precipitation was also followed by the registration of
the UV spectrum in the moment of pH change, after 1 h and after 24 h.
2.7. Methods for analysis of solid phase
2.7.1. XRPD
Following the solubility measurement, small amount of the solid
phase was isolated and dried to a glass plate. X-ray powder diffraction
patterns of these samples were recorded using a PANalytical (Amelo,
The Netherlands) X'pert ProMDP X-ray diffractometer using Cu-Kα ra-
diation (1.524 Ǻ) and a Ni filter. The applied voltage was 40 kV, while
the current was 30 mA. The samples were analysed between 4° and 42°
2Ɵ.
2.7.2. SEM
Morphology of the samples (crystalline Form A and Form B) was
studied by SEM using JEOL JSM-5500 LV electron microscope (JEOL
Ltd., Tokyo, Japan) with an excitation voltage of 5–20 kV.
2.7.3. IR
Infrared spectra (4000–400 cm−1) of solid samples were recorded
using a Bruker Tensor 37 type Fourier transform infrared (FTIR) spec-
trometer (Bruker Corporation, Billerica, MA, USA) equipped with DTGS
(deuterated triglycine sulphate) detector with a resolution of 4 cm−1.
Before testing, the samples were mixed with potassium bromide (KBr)
powder and cold-pressed into a suitable disk for FTIR measurement.
2.8. Statistical analysis
The concentrations were expressed as means± SD, and were com-
pared using ‘two-sample’ Student's t-test. The differences were con-
sidered statistically significant when p < 0.05.
3. Results and discussion
Oxytetracycline hydrochloride, a broad-spectrum antibiotic of the
tetracycline family was introduced into therapy by Pfizer in 1950. For
decades, it was commonly used all over the world in the treatment of
infections caused by Gram positive or Gram negative bacteria. As of
today, some strains of bacteria had developed resistance against it, its
usage has decreased. However, due to its low price, it is still prevalent
in developing countries and in veterinary medicine. OTC is a triprotic
ampholyte compound, having two acidic (pKa1: 3.23 and pKa2: 7.22)
ionisation sites and a basic (pKa3: 8.82) one [Tam and Takács-
Novák, 2001]. Its isoelectric point is at pH 5.2, where the compound is
present in zwitterionic form. The distribution profile of different pro-
tonation forms of OTC is shown in Fig. 1. As visible, the ionisation of
the compound happens mostly in the physiologically relevant pH range
(1–8), its solubility is strongly pH-dependent.
Several polymorphic forms of OTCH are known and characterized
[Toro et al., 2007], but out of them two, namely, Form A and Form B,
are used in pharmaceutical formulations. They are in monotropic re-
lationship and exhibit different morphology (Fig. 2). Form A is the
thermodynamically stable polymorph, having brownish-yellow colour,
204 °C melting point, and 1.496 g/cm3 density, while Form B is a
metastable (kinetic) polymorph, a hygroscopic, brilliant yellow colour
powder with a melting temperature of 180–195 °C, and 1.440 g/cm3
density. SEM images show different crystal habits of the two forms
(Fig. 2). IR spectra (Fig. 3) were used for identification compared with
those published by Burger et al. (1986). According to Burger the hy-
groscopicity of the two polymorphs differs greatly, this way they can be
identified based on the water peak in the IR spectra. Form B is more
hygroscopic, showing a characteristic broad peak between 3400–3600
1/cm.
3.1. Equilibrium solubility measured in pH range 4–7.4
The equilibrium solubility of OTCH Form A and B as starting
Table 1
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materials was measured by the standard protocol of SSF method at 4
different points in pH range 4.0–7.4, at 25 °C. In the experiments, we
followed all the recommendations suggested in the recently published
consensus-based ‘white paper’ about the good practice of solubility
measurements in order to improve the quality of solubility data
[Avdeef et al., 2016]. The SpH ± SD results are expressed in µg/mL
unit as the average value of 3 parallel measurements, and are sum-
marized in Table 2. The standard deviation was within the range of
1.5–6.7%, average SD: 3.0%. This SD value fully corresponds to that
found in the validation study of SSF method using the standardized
protocol (6 h stirring followed by 18 h sedimentation) [Baka et al.,
2008]. No significant difference was found between the SpH values of
the samples in the pH region 4.0–7.4. This can be explained with the
transition of polymorphs to a same polymorph under the experimental
conditions, as supported by the solid phase analysis (see below).
The results exhibit the typical solubility-pH profile of an ampholyte
molecule. The solubility is the lowest at (and near to) the i.e. point pH
Fig. 1. Structure (a) and distribution profile of OTC (b).
Fig. 2. Morphology of OTCH polymorphs (visual appearance of the solid (a); SEM images: (b) Form A, (c) Form B).
Fig. 3. IR spectra of OTCH polymorphs.
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(5.2 ± 0.5 in this case) and this value corresponds to the intrinsic
solubility (So) of the compound. Towards the lower and higher pH
values, - due to ionization - the solubility increases as determined by the
Henderson–Hasselbalch (HH) equation [Völgyi et al., 2010]. The
average solubility value obtained at pH 5, at 25 °C, is 313 ± 21 µg/mL
(logSo [M]: −3.200) (n = 6), which can be considered as the intrinsic
solubility of OTCH in aqueous medium.
Solubility of OTCH shows very slight temperature-dependence be-
tween 25 and 37 °C, experiments performed at the physiological tem-
perature resulted in logSo [M]: −3.02 (n = 4). Therefore further ex-
periments were conducted at 25 °C.
3.2. Solid phase analysis in pH range 4–7.4
First the X-ray powder diffraction patterns of the starting materials,
Form A and Form B were registered (see in Fig. 4). Next, the solid
phases - isolated and dried from the solubility suspension after in-
cubation at different pHs - were studied. Diffractograms shown in Fig. 4
demonstrate that the samples are not identical with the starting poly-
morphic forms in either case, since the characteristic peaks of the
starting polymorphs cannot be found in the diffractogram of the iso-
lated sample. The results indicate that both polymorphs recrystallized
to a common form. It was identified as oxytetracycline dihydrate with
the help of the Cambridge Structural Database (reference code: OX-
TETD). The above results of solid phase analysis confirm and can ex-
plain the equilibrium solubility data measured experimentally
(Table 2). The conversion of different polymorphic forms to an identical
product is a common, possible behaviour of drugs: a similar phenom-
enon was found recently in the case of venlafaxine hydrochloride
[Takács-Novák et al., 2019].
3.3. Real-time monitoring of dissolution, supersaturation and equilibration
time at pH 5.0
As the determination of the equilibrium solubility of the poly-
morphs in water is prohibited by the conversion to dihydrate, next, we
studied the dissolution kinetics of the two forms in BR buffer at pH 5.0.
The in situ real-time monitoring of dissolution was conducted
immersing an ATR-UV probe to the solubility suspension and attaching
to the µDISS Profiler™. The application of the ATR-UV probe was ne-
cessary, because the concentration of the OTCH solutions was too high
for the direct measurement with the smallest (2 mm) available tip of the
µDISS instrument. ATR-UV is a specially designed and crafted probe
containing a sapphire crystal and fibre optic. It makes measuring highly
concentrated solutions possible, because the UV light goes through only
a few µm pathlength of the sample (Simon et al., 2015).
In a pilot experiment, the 0–24 h monitoring of dissolution showed
immediate dissolution and a short (~10–12 min) time needed to reach
the equilibrium. Therefore, further parallel experiments were con-
ducted up to 60 min. The average concentration values and the SD bars
are presented in Fig. 5. a panel. Enlarging the 0–10 min period (in
Fig. 5. b panel) shows the identical dissolution performance of the two
forms. At pH 5.0 no significant difference is in the extent of super-
saturation (Smax: 549 µg/ml Form A vs 536 µg/ml Form B) which has
been reached around 1 min. Precipitation starts at this point and
reaching the solubility equilibrium around 10 min, the concentration of
the saturated solution (that is, the solubility) has not changed. The
identical dissolution kinetic supports the immediate conversion of the
two forms to the common dihydrate product at this pH. Intrinsic solu-
bility measured by the ATR-UV probe, at 25 °C, is 308 ± 26 µg/mL
(logSo [M]: −3.207) (n = 6), which is in perfect agreement with So
obtained by the SSF method.
3.4. Solubility analysis in SGF
As the above results show, neither the intrinsic solubility nor the
dissolution kinetic at pH 5.0 can explain the therapeutic none-
quivalence of OTCH polymorphs. So, we extended the study to the
solubility analysis in SGF, despite the fact that in acidic pH, OTCH
dissolves very well, and the high-concentration saturated solution may
behave as a non-ideal liquid. Further on, the decomposition of OTCH in
acidic medium in such concentration may also cause difficulties, even
though - according to literature data - the diluted aqueous solutions of
OTCH at pH 1.0–2.5 are stable for at least 30 days at 25 °C [The Merck
Index, 2001].
The kinetic solubility in SGF was determined with a simplified ap-
proach (described in Section 2.5). The temperature effect (37 vs 25 °C)
on solubility at this pH was also negligible (less than 30%) thus we
discuss the results obtained at 25 °C in order to be comparable with the
literature data. The two polymorphs have different values: SpH1.2:
205 mg/mL for Form A vs 385 mg/mL for Form B. The higher kinetic
solubility of the metastable form can be explained by its 2.6 times
higher specific surface relative to the other form [US Patent, 1959,
US2867661]. Though these solubility values can be considered as ap-
proximate data, as the number of analysed samples was limited due to
the excessive amount of OTCH required at this pH, they reflect the (~
1.9 times) better solubility of Form B. This perfectly corresponds with
the ratio of metastable/stable polymorph solubility found to be typi-
cally less than 2 by Pudipeddi and Serajuddin (2005) surveying lit-
erature data.
The real-time analysis of dissolution with the ATR-UV probe sup-
ported the above results. The drug concentration versus time profile in
the first 0–1 h period is shown in Fig. 6. The metastable Form B dis-
solves fast and reaches a substantial supersaturation in minutes (Smax:
718 mg/mL at 7 min) then precipitation causes a decrease in the so-
lution concentration. At about 30 min, a sharp decrease in the con-
centration accompanied by a distortion of the UV spectrum can be
observed indicating either the decomposition or the transition of the
solute. The behaviour of the stable Form A is markedly different,
showing immediate dissolution (Smax: 436 mg/mL at 6.5 min) without
supersaturation. The UV spectrum of this sample is unchanged during
the solubility experiment.
Solid phases were analysed by XRPD with samples taken out from
the solubility suspension at 1 h and 24 h, and shown in Fig 7. While in
Table 2
Equilibrium solubility of OTC dihydrate in Britton–Robinson buffer at 25 °C
measured by SSF method using Form A and Form B as starting materials.
pH SpH ± SD (µg/mL)
Form A Form B
4.0 345 ± 7 325 ± 22
5.0 328 ± 5 298 ± 5
6.5 668 ± 36 693 ± 10
7.4 1721 ± 40 1816 ± 60
Fig. 4. XRPD patterns of OTCH Form A and B and the solids isolated from
solubility suspensions at different pH values.
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the case of Form A, the solid phase has not changed, and its pattern is
identical with the starting material, in case of Form B, solid phase al-
ready at 1 h shows a different pattern, indicating a decomposition/
transition process of the metastable polymorph. Consequently, from
real-time monitoring experiments, the equilibrium solubility could not
be obtained, but the dissolution kinetic in SGF at least in the first 1 h
(which is relevant with the gastric residence time) revealed sig-
nificantly different performances of the two polymorphs.
Above results are in accordance with findings reported by
Burger et al. (1986). They suggested keeping the pH below 1.5 in order
to avoid the conversion of these polymorphs to dihydrate, where the
process is hindered or very slow.
3.5. Effect of pH-change from 1.2 to 5.0
For simulating the gastric-small intestine transfer, the effect of pH
change was investigated. Considering that the oral dose of OTCH is
500 mg and the gastric fluid in the stomach is estimated to be around
250 mL according to recent studies, a 2 mg/mL OTCH solution was
prepared of Form A in SGF (pH 1.2). (This concentration is well below
the solubility of both polymorphs in SGF). The acidic media was con-
verted to duodenum pH 5.0, where precipitation can be expected based
on the intrinsic solubility of the API. Surprisingly, the supersaturated
solution with the concentration of 1.63 mg/mL (around 5 times the
concentration of the intrinsic solubility) was stable for over 1 h, while
no precipitation was observed with the spectrophotometer. Since the
molecule is neutral (in zwitterionic form) at this pH, having the least
polarity/highest lipophilicity, the absorption from this compartment of
the GI tract can be expected. Supersaturation/precipitation is influ-
enced by the individual intestinal pH and/or the food consumed, which
can lead to different absorption and blood-level.
4. Conclusion
In this study, we conducted the comprehensive solubility analysis of
two polymorphic forms of OTCH including equilibrium solubility
measurements by the SSF method in a biorelevant pH range, and
monitoring the dissolution behaviour of the two polymorphic forms in
real-time at different pH values. Our work demonstrates the importance
of solid phase analysis in the solubility investigation of drug poly-
morphs providing reliable information about which form is present in
solubility equilibrium.
We proved that the determination of the equilibrium solubility of
OTCH polymorphs in pH range 4–7.4 is hindered by the conversion of
the starting materials to a common dihydrate form during solubility
equilibration. The obtained results indicate the pH-dependent solubility
of OTC dihydrate.
With this, we put an end to a long-lasting, false citation chain about
the 28 times aqueous intrinsic solubility difference of OTCH poly-
morphs. We revealed that the cited data from ref. Burger et al. (1986)
was originally measured in isopropanol, not in water. In IPA the poly-
morphs keep their original form during the solubility experiment and
the metastable form dissolves much better in this organic solvent. But
Fig. 5. Real-time monitoring of concentration vs time profile of OTCH Form A and Form B in BR buffer pH 5.0 with ATR-UV probe (a panel: 0–60 min, b panel:
0–10 min).
Fig. 6. Real-time monitoring of concentration vs time profile of OTCH Form A
and Form B in SGF pH 1.2 with ATR-UV probe.
Fig. 7. XRPD patterns of OTCH Form A and B and the solids isolated from
solubility suspensions at pH 1.2.
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this phenomenon does not exist in aqueous medium.
The real time monitoring of dissolution at pH 5.0 and 1.2 with an
ATR-UV probe attached to the µDISS Profiler provided further in-
formation about the dissolution performance of polymorphs being in
complete agreement with the SSF results.
The difference in the kinetic solubility and dissolution performance
of the polymorphs found in SGF and supersaturation occurring on pH-
change 1.2 → 5.0 may contribute to the interpretation of the ther-
apeutic nonequivalence of solid OTCH products.
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